Our current technical analysis of Benitec Biopharma (NASDAQ:BNTC)


USD 0.17  0.02  10.53%   

As many millenniums are trying to avoid healthcare space, it makes sense to go over Benitec Biopharma a little further and try to understand its current market patterns. For many short-term oriented investors Benitec Biopharma may not be the right move right now, but if you are here for the long run, it may be worthy of a closer look. A lot of the movements of the company stock price movements has been a reflection of what is happening in the market overall. Weak basic indicators of the company may also suggest signs of long term losses for Benitec investors. Benitec Biopharma is scheduled to announce its earnings tomorrow.
Published over two months ago
View all stories for Benitec Biopharma | View All Stories
The company's average rating is Hold from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Benitec Biopharma market sentiment investors' perception of the future value of Benitec. Let us look at a few aspects of Benitec technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Benitec Biopharma. In general, we focus on analyzing Benitec Biopharma stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Benitec Biopharma's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Benitec Biopharma's intrinsic value. In addition to deriving basic predictive indicators for Benitec Biopharma, we also check how macroeconomic factors affect Benitec Biopharma price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Benitec Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Benitec Biopharma in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Benitec Biopharma. Your research has to be compared to or analyzed against Benitec Biopharma's peers to derive any actionable benefits. When done correctly, Benitec Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Benitec Biopharma.

Watch out for price decline

Please consider monitoring Benitec Biopharma on a daily basis if you are holding a position in it. Benitec Biopharma is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Benitec Biopharma stock to be traded above the $1 level to remain listed. If Benitec Biopharma stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Benitec Biopharma's Liquidity

Benitec Biopharma financial leverage refers to using borrowed capital as a funding source to finance Benitec Biopharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Benitec Biopharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Benitec Biopharma's total debt and its cash.

How does Benitec utilize its cash?

To perform a cash flow analysis of Benitec Biopharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Benitec Biopharma is receiving and how much cash it distributes out in a given period. The Benitec Biopharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Peter Francis of 12000 shares of Benitec Biopharma subject to Rule 16b-3

Legal trades by Benitec Biopharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Benitec insider trading alert for grant of options (right to buy) by Peter Francis, the corporate stakeholder, on 10th of December 2021. This event was filed by Benitec Biopharma Inc with SEC on 2021-12-10. Statement of changes in beneficial ownership - SEC Form 4. Peter Francis currently serves as independent non-executive chairman of the board of Benitec Biopharma [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Benitec Biopharma

Benitec Biopharma has a beta of 1.1677. Let's try to break down what Benitec's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Benitec Biopharma will likely underperform. The beta indicator helps investors understand whether Benitec Biopharma moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Benitec deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity reported the previous year's revenue of 75 K. Net Loss for the year was (17.14 M) with profit before overhead, payroll, taxes, and interest of 287 K.

Over 3 percent rise for Benitec Biopharma. What does it mean for investors?

Coefficient Of Variation just dropped to -543.13, may suggest upcoming price decrease. Benitec Biopharma is displaying above-average volatility over the selected time horizon. Investors should scrutinize Benitec Biopharma independently to ensure intended market timing strategies are aligned with expectations about Benitec Biopharma volatility. Benitec Biopharma is a potential penny stock. Although Benitec Biopharma may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Benitec Biopharma. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Benitec instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Takeaway on Benitec Biopharma Investment

Whereas some companies in the biotechnology industry are either recovering or due for a correction, Benitec Biopharma may not be performing as strong as the other in terms of long-term growth potentials. With a less-than optimistic outlook for your 90 days horizon, it may be a good time to sell some or all of your Benitec Biopharma holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Benitec Biopharma.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Benitec Biopharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com